Liraglutide Drug Asset Due Diligence Report 2026

This Liraglutide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

562

Registered trials

420

Result records

148

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Liraglutide can convert its Recombinant polypeptide profile and GLP-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Liraglutide (query alias: liraglutide)
Modality / target	Recombinant polypeptide; GLP-1R; GLP-1R agonists
Highest global status	Approved
Originator	Novo Nordisk A/S
Active developers	Nanexa AB, Novo Nordisk A/S, Izmir Ekonomi Üniversitesi

The MCP disease footprint includes Obesity, Overweight, Diabetes Mellitus, Type 2. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07374445	Phase 4	Completed	100	Change in %TWL from baseline to endpoint across patient groups
NCT07590219	Phase 4	Active, not recruiting	30	Change in Body Mass Index (BMI)
NCT07337174	Phase 1	Not yet recruiting	40	Cmax following single-dose administration

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Do GLP-1s SCAR? A FAERS Disproportionality Analysis of Severe Cutaneous Adverse Reactions to GLP-1 Receptor Agonists

Not Applicable; n=917; evaluation: Negative. Reported fields: -; -; Disability = 10.0 %

GLP-1 receptor agonists-associated skin events: identifying the most common culprits and reactions

Not Applicable; n=15780; evaluation: Positive. Reported fields: AE = common AEs were rash (26.1%), pruritus (22.1%), alopecia (14.8%), hyperhidrosis (14.6%), and urticaria (3.5%). % ; AE = common AEs were rash (26.1%), pruritus (22.1%), alopecia (14.8%), hyperhidrosis (14.6%), and urticaria (3.5%). % ; AE = 14.8 %

Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study

Phase 3; n=7850; evaluation: not stated. Reported fields: -; -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Liraglutide addresses Obesity, Overweight, Diabetes Mellitus, Type 2. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Recombinant polypeptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 148 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: GLP-1R records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-07-07	Novo Nordisk pens long-acting GLP-1 implant tech deal with Vivani Medical	Phase 1	Financial terms not disclosed
2026-06-10	Hetero Labs, Hungary’s Gedeon Richter to collaborate for Semaglutide	Discovery	Financial terms not disclosed
2026-06-04	博安生物度拉糖肽注射液完成在美授权	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO